Subacute ivermectin–induced affective dysregulation: Evidence for hippocampal microglial and astrocytic activation

MakaleYalnız künyeScopus SJRQ1

Özet

Ivermectin (IVR) is a semi-synthetic macrocyclic lactone widely used against nematodes. Under physiological conditions, its central nervous system (CNS) penetration is limited by P-glycoprotein–mediated efflux at the blood–brain barrier (BBB). Nevertheless, supratherapeutic dosing, BBB-compromising pathologies, concomitant P-glycoprotein inhibitors, or MDR1 variants can enhance CNS entry and precipitate neurotoxicity. To evaluate behavioural and neuroinflammatory sequelae of subacute exposure, rats received IVR (1, 5, or 10 mg/kg; i.p.) once daily for 21 days. Animals were assessed for motor function (activity cage, Rota-rod), affective behaviour (elevated plus maze, modified forced swim test), and cognition (Morris water maze). Assay validation employed diazepam (1 and 3 mg/kg; i.p.), desipramine (30 mg/kg; i.p.), and piracetam (200 mg/kg; i.p.), administered according to their respective protocols. IVR did not alter motor performance or spatial learning and memory across doses. However, 5 and 10 mg/kg reduced the percentage of open-arm entries and increased immobility, consistent with anxiety- and depression-like phenotypes, respectively. At 10 mg/kg, hippocampal immunohistochemistry revealed increased Iba1 and GFAP immunoreactivity within CA1, indicating microglial and astrocytic activation. Quantitative counts demonstrated no significant change in CA1 neuronal number across treatment groups, implying that the observed glial activation occurred in the absence of detectable neuronal loss. Collectively, our data indicate that subacute, high-dose IVR provokes affective behavioural alterations coupled to hippocampal neuroinflammation, while sparing gross motor function and measurable cognitive performance under the present conditions. These findings underscore caution when administering IVR at elevated doses or in settings that compromise BBB integrity and warrant further mechanistic and time-resolved investigation.

Anahtar Kelimeler

RDL Kalıcı Bağlantı (PID)
https://rdlopen.rawdatalibrary.net/r/bayburt/11360Resmi atıflarda kullanılan kalıcı adres
DOI
https://doi.org/10.1016/j.rvsc.2026.106105Yayıncı resmi DOI adresi
İndeks kayıtları
Kaydın indeks veri tabanlarındaki sayfası (aktarımda alınan kayıt numarasıyla). Erişim, indeksin kendi koşullarına bağlıdır.
Atıflar
Scopus
0
WoS
0
Her kaynağın kendi saydığı toplam atıf; aktarım ve zenginleştirme sırasında alındı.
Tam Kayıt
AlanDeğerDil
dc.contributor.authorEser, Mustafa
dc.contributor.authorYazıcı, Cevşen
dc.contributor.authorKandemir, Ümmühan
dc.contributor.authorÜçel, Umut İrfan
dc.contributor.authorBozkurt, Mehmet Fatih
dc.contributor.authorDemir Özkay, Ümide
dc.contributor.authorCan, Özgür Devrim
dc.date.accessioned2026-10-29T19:08:18.642936955Z
dc.date.available2026-10-29T19:08:18.642936955Z
dc.date.issued2026
dc.description.abstractIvermectin (IVR) is a semi-synthetic macrocyclic lactone widely used against nematodes. Under physiological conditions, its central nervous system (CNS) penetration is limited by P-glycoprotein–mediated efflux at the blood–brain barrier (BBB). Nevertheless, supratherapeutic dosing, BBB-compromising pathologies, concomitant P-glycoprotein inhibitors, or MDR1 variants can enhance CNS entry and precipitate neurotoxicity. To evaluate behavioural and neuroinflammatory sequelae of subacute exposure, rats received IVR (1, 5, or 10 mg/kg; i.p.) once daily for 21 days. Animals were assessed for motor function (activity cage, Rota-rod), affective behaviour (elevated plus maze, modified forced swim test), and cognition (Morris water maze). Assay validation employed diazepam (1 and 3 mg/kg; i.p.), desipramine (30 mg/kg; i.p.), and piracetam (200 mg/kg; i.p.), administered according to their respective protocols. IVR did not alter motor performance or spatial learning and memory across doses. However, 5 and 10 mg/kg reduced the percentage of open-arm entries and increased immobility, consistent with anxiety- and depression-like phenotypes, respectively. At 10 mg/kg, hippocampal immunohistochemistry revealed increased Iba1 and GFAP immunoreactivity within CA1, indicating microglial and astrocytic activation. Quantitative counts demonstrated no significant change in CA1 neuronal number across treatment groups, implying that the observed glial activation occurred in the absence of detectable neuronal loss. Collectively, our data indicate that subacute, high-dose IVR provokes affective behavioural alterations coupled to hippocampal neuroinflammation, while sparing gross motor function and measurable cognitive performance under the present conditions. These findings underscore caution when administering IVR at elevated doses or in settings that compromise BBB integrity and warrant further mechanistic and time-resolved investigation.
dc.description.sponsorshipAnadolu Üniversitesi, (2108S188)
dc.identifier.articlenumber106105
dc.identifier.doi10.1016/j.rvsc.2026.106105
dc.identifier.eissn1532-2661
dc.identifier.issn0034-5288
dc.identifier.pmid41707433
dc.identifier.scopus2-s2.0-105030097832
dc.identifier.urihttps://rdlopen.rawdatalibrary.net/r/bayburt/11360
dc.identifier.volume203
dc.identifier.wosWOS:001695258500001
dc.language.isoen
dc.publisherElsevier B.V.
dc.relation.ispartofResearch in Veterinary Science
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectAffective behaviour
dc.subjectAstrocytes
dc.subjectHippocampus
dc.subjectIvermectin
dc.subjectMicroglia
dc.subject.classificationVeterinary Sciences
dc.subject.otherAnimals
dc.subject.otherAstrocytes
dc.subject.otherBehavior, Animal
dc.subject.otherHippocampus
dc.subject.otherIvermectin
dc.subject.otherMale
dc.subject.otherMicroglia
dc.subject.otherRats
dc.subject.otherRats, Wistar
dc.subject.othercarrier proteins and binding proteins
dc.subject.otherdesipramine
dc.subject.otherdiazepam
dc.subject.otherglial fibrillary acidic protein
dc.subject.otherIba1 protein
dc.subject.otherpiracetam
dc.subject.otherunclassified drug
dc.subject.otheractivity cage test
dc.subject.otheradult
dc.subject.otheraffective dysregulation
dc.subject.otheranimal tissue
dc.subject.otheranxiety
dc.subject.otherArticle
dc.subject.otherastrocyte
dc.subject.otherblood brain barrier
dc.subject.othercell activation
dc.subject.othercontrolled study
dc.subject.otherdepression
dc.subject.otherelevated plus maze test
dc.subject.otheremotional disorder
dc.subject.otherexperimental behavioral test
dc.subject.otherexposure
dc.subject.otherforced swim test
dc.subject.otherhippocampal CA1 region
dc.subject.otherimmobility
dc.subject.otherimmunohistochemistry
dc.subject.otherimmunoreactivity
dc.subject.othermemory
dc.subject.othermental performance
dc.subject.otherMorris water maze test
dc.subject.othermotor performance
dc.subject.othernervous system inflammation
dc.subject.othernonhuman
dc.subject.otherphenotype
dc.subject.otherrat
dc.subject.otherrotarod test
dc.subject.otherspatial learning
dc.subject.otherSprague Dawley rat
dc.subject.othersubacute exposure
dc.subject.otheranimal
dc.subject.otheranimal behavior
dc.subject.otherdrug effect
dc.subject.otherWistar rat
dc.titleSubacute ivermectin–induced affective dysregulation: Evidence for hippocampal microglial and astrocytic activation
dc.typeArticle
rdl.citation.scopus0
rdl.citation.wos0
rdl.departmentAnadolu University, Faculty of Pharmacy, Department of Pharmaceutical Microbiology, Eskişehir, Türkiye
rdl.departmentAnadolu University, Faculty of Pharmacy, Department of Pharmacology, Eskişehir, Türkiye
rdl.departmentBilecik Şeyh Edebali University, Faculty of Medicine, Department of Medical Pharmacology, Bilecik, Türkiye
rdl.departmentBayburt University, Vocational School of Health Services, Department of Pharmacy Services, Bayburt, Türkiye
rdl.departmentAfyon Kocatepe University, Faculty of Veterinary Medicine, Department of Pathology, Afyon, Türkiye
rdl.oa.statusclosed
rdl.scopus.quartileQ1
rdl.source.indexSCOPUS
rdl.source.indexWOS
rdl.source.indexPUBMED
rdl.wos.indexScience Citation Index Expanded (SCI-EXPANDED)